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Abstract
Summary We have examined the changes induced in the
trochanteric region of femur of ovariectomized rat after
administration of estradiol and p.arathyroid hormone. We
have developed a reproducible biomechanical test and
produced trochanteric fractures to evaluate stiffness and
strength of this region in addition to histomorphometry.
Introduction We investigated the short-term effects of
parathyroid hormone (PTH) and estrogen (E) on the
strength of the rat trochanteric region in a new mechanical
test.
Methods Forty-four 3-month-old female Sprague–Dawley
rats were ovariectomized and 8 weeks later treated with
soy-free diet (C), daily applications of orally supplied E
(0.5 mg/kg food) or subcutaneously injected PTH
(0.014 mg/kg), for 5 weeks, and an additional untreated
group was added as sham-operated. The femurs were
examined for biomechanical and histomorphometric
changes.
Results Our new mechanical test was validated in a
right–left comparison. The PTH treatment induced sig-
nificantly superior biomechanical results (Fmax=225.3 N,
stiffness=314.9 N/mm) compared to E (Fmax=182.9 N,
stiffness=237.2 N/mm), C (Fmax=166.03 N, stiffness=
235.56 N/mm), and sham (Fmax=192.1 N, stiffness=
267.2 N/mm). Animals of the PTH group demonstrated a
significantly improved trabecular bone structure and area
(75.67%) in comparison to the E (61.04%) and C (57.18%)
groups.
Conclusion Our new biomechanical test is valid and
produces trochanteric fracture. Our results show that
the short-term antiosteoporotic effects of PTH are in
the trochanteric region of ovariectomized rat superior
to E.
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Estrogen, the predominant female sex hormone, has
commonly been considered the most important non-
mechanical (endocrine) regulator of bone metabolism [1].
Estradiol esters and conjugated estrogens have strong
suppressive effects on climacteric complaints, as they
prevent or decelerate osteoporotic activities in the bone.
However, long-term estrogen treatments are accompanied
by the undesired side effects of increased risk of mammary
cancer, strokes, and thrombo-embolism [2, 3].
In addition to serum calcium regulation and stimulation
of bone resorption [4], parathyroid hormone (PTH) is
known to stimulate bone formation under certain conditions
[5]. It is also known that PTH can cause bone resorption
and is thus associated with both anabolic and catabolic
activities [6–10]. The possibility that PTH has paradoxical
effects on bone was first proposed by Selye in 1932 after he
observed that continuous infusion in vivo of crude
preparations of PTH-elevated bone formation and also
dominantly bone resorption, while intermittent administra-
tion of the hormone resulted mainly in a stimulation of
bone formation especially at the trabecular surface. Later
studies have emphasized the importance of evaluating the
effects of PTH not only in the trabecular region but also in
cortical areas.
The ovariectomized (OVX) rat serves as a validated
experimental model of post-menopausal osteoporosis. Ani-
mals develop substantial osteoporosis within a few months
after ovariectomy [11]. The proximal metaphysis of the
tibia and lumbar vertebrae are suitable common sites used
to investigate bone histomorphometric and mechanical
changes in this rodent osteoporosis model. These regions,
however, have a high content of trabecular bone, but a very
thin cortical shell [12, 13]. Next to the femoral neck
fracture, the trochanteric fracture is one of the most
common fracture types of the proximal femur in human,
especially in patients with progressive osteoporosis. This
part of the femur contains both trabecular and cortical bone,
in contrast to the femoral shaft. The trochanteric part of
femur therefore seems to be a further and additional
important area to investigate the biomechanical changes
induced after treatment with antiosteoporosis drugs such as
parathyroid hormone, which appear to rapidly influence
both cortical and trabecular bone formation. The known
sufficient and thick muscle insertions (cuff) in this region
make this skeletal site also interesting for evaluating the
effect of mechanical stimulations like whole body vibra-
tions (like high-frequency, low-magnitude mechanical
stimulations).
To the best of our knowledge, there are no published
studies that have used mechanical tests to characterize the
trochanteric region of the femur to date, presumably
because of the many problems encountered in designing a
reproducible bending and breaking test in this location. The
most conventional methods for evaluating rat hip failure are
based on axial compression approaches [14]. However, as
most osteoporotic hip fractures result from lateral falls, it is
necessary to establish additional mechanical testing meth-
ods that more closely resemble clinical conditions (lateral
loading). It is also necessary to study the effects of
antiosteoporosis drugs in skeletal sites that exhibit both
sizeable trabecular and cortical areas with an intact periost
covering.
In this work, we used histomorphometric and biome-
chanical tests to study the changes in the trochanteric region
of femur of ovariectomized rat after administration of E or
PTH. To evaluate the biomechanical changes in rat
trochanteric region after drug treatment, it was necessary
first to produce a trochanteric fracture.
Materials and methods
Development of a new breaking test for the trochanteric
region of the rat femur
A novel mechanical loading configuration was developed
to measure the strength of the trochanteric region of the
femur, according to the design of one of the authors (K.M.
Stuermer). The left and right femurs of non-OVX rats were
tested in a direction vertical to the greater trochanter. The
femoral head was fixed in a 4 mm deepening at one end of
the system, while the femoral shaft was horizontally
positioned between two metallic movable rolling cylinders.
The distal end of the femur was in contact with the
aluminum plate without any rigidity. The lesser trochanter
did not come into contact with the aluminum plate at all
because of a groove made to allow for free movement. The
angle between the femoral shaft and the horizontal line was
nearly 0°. Force was applied vertically to the greater
trochanter using a roller stamp (Fig. 1a–c).
The force was applied with a ZWICK-testing machine,
type 145660 Z020/TND (Zwick/Roell, Ulm, Germany).
The measurement range was from 2 to 400 N, at a relative
accuracy of 0.2% at 0.4% nominal force (FN). During the
bending and breaking test, the femur was allowed to move
longitudinally as it was dynamically fixed between the two
roller clamps. The stamp was driven down to the greater
trochanter until the bone was broken. Displacement and
load were recorded, and ultimate strength (maximal load,
N), stiffness (slope of the linear part of the curve,
representing elastic deformation, N/mm), and the yield load
were calculated.
Fifteen pairs of right–left femurs of non-OVX rats
were studied with this new breaking test before starting
252 Osteoporos Int (2010) 21:251–261the comparative bioassay. Each bone and its contralat-
eral partner underwent the breaking test on the same
day, and the test order of bones was random. All bones
were analyzed by the same operator.
Comparative bioassay
Experimental animals and substances
The experiments were carried out using 44 3-month-old
female Sprague–Dawley rats fed with a standard diet ad
libitum. The animals were randomized by weight into
four experimental groups (n=11 in each group): OVX
soy-free group (C), PTH group receiving daily subcuta-
neous injections of 0.014 mg/kg 1,34 parathyroid hor-
mone, and the estrogen (E) group receiving 15 g/day food,
so the average E intake was 0.5 mg E/day corresponding
to 0.325 mg free 17-β-estradiol, and an untreated non-
OVX group was added as sham-operated group. The
experimental procedures were approved by the local
ethics commission under German animal protection law
(permission from 11.03.1998, AZ: 509.42502/01-02.98
Bezirkregierung Braunschweig). Eight weeks before
starting the drug treatments, bilateral ovariectomy was
performed. After 5 weeks of drug treatments, the rats
were euthanized, and bilateral femurs were dissected
free of soft tissue and then submitted to biomechanical
and histomorphometric tests.
Intravital fluorochrome labeling
During the 35 days of drug treatment, animals were
subcutaneously injected with four fluorescent agents
(Merck, Darmstadt, Germany) to label the process of
bone formation and restoration. The following fluoro-
chromes were used: xylenol orange (90 mg/kg) on
day 13, calcein green (10 mg/kg) on day 18, alizarin
red (30 mg/kg) on day 24, and tetracycline (25 mg/kg)
on day 35. The results of the fluorochrome labeling
were analyzed quantitatively in the cross sections of
femurs 11 mm distal from femoral head in the
subtrochanteric region. Evaluation of the changes and
the localization of bone formation in the cortical surface
was the aim of fluorochrome analysis.
Biomechanical test
During the breaking test, the actual strength was
recorded every 0.1 mm during the lowering of the
stamp. The testXpert software continuously recorded the
force applied until total failure of the bone occurred.
After the failure, the software program indicated the
maximum load (Fmax) and the breaking strength. The
breaking strength is the last measured point of the running
graph and has no explanatory power. In the right–left
comparison and the comparative bioassay, Fmax is the
highest force that the femur can withstand.
A c c o r d i n gt ot h em e t h o dd e s c r i b e di nS t u e r m e re ta l .
(2006), increases in elastic deformation (stiffness =
elasticity) were calculated, and the transition point of
elastic to plastic deformation was determined from the
digital data [15]. This point represents the yield load of the
bone. To determine this point, we calculated a regression
line and the standard deviation (SD) with the individual
data of the linear part of the graph. We defined the
transition point of elastic to plastic deformation as a
decrease of stiffness of more than twice the SD.
X-ray examination of fracture mode
Radiographs in the anterior–posterior and lateral view of all
femurs tested in the comparative bioassay were taken. A
Fig. 1 a–c The new breaking test is designed to produce trochanteric
fractures for studying of biomechanical strength of trochanteric region
of rat femur (here femur of Sprague–Dawley rat). The femoral head
was fixed in a 4-mm deepening on the other end of the system. The
femoral shaft was horizontal between two metallic movable rolling
cylinders. The distal end of the femur was in contact with the
aluminum plate without any rigidity. The force was applied with a
ZWICK-testing machine, type 145660 Z020/TND (Zwick/Roell, Ulm,
Germany)
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cabinet X-ray system (model 43855A; Faxitron X-ray
System) with 40 kV were used.
Bone histomorphometry and cancellous bone structure
analysis
The undecalcified femurs were dissected and carefully
cleaned of clinging soft tissues, fixed in 70% ethanol for
48 h, dehydrated through an alcohol gradient, and embed-
ded in methyl methacrylate. Serial sagittal sections (150 µm
thick) through the proximal femur were cut with a
microtome (Leica, Sägemikrotom 1600). The region of
interest for the histomorphometric test was a frame where
the proximal part of femur included the head (without
epiphysis), neck, and trochanteric region. The microradio-
graphs of the sagittal sections were used to measure
structural indices of both trabecular and cortical bone areas.
A digitizing morphometric system was used to measure
bone histomorphometric parameters. The system consisted
of a microscope (Leica-System MZ 7.5), a digitizing pad
coupled to a PC, and a morphometry program (Qwin
software).
The epiphysis line of the capitis femoris represented the
proximal border of the histomorphometry frame. The distal
limit of the sections was marked by the base of the major
trochanter (Fig. 5a–d). We assessed ratio of trabecular bone
area to total cancellous bone area at the prox. Femur (Tb.
Ar) and trabecular connectivity (N. Nd/mm
2) and trabecular
thickness (Tb.Wi).
It is known that minimal changes in cortical surface
occur first a long time after OVX. The Ct.Wi between all of
the rat groups shows often a large standard deviation within
each group, and the real changes in this region remain
difficult to measure. In our study, we measured the ratio
between bone diameter and marrow diameter (B.Dm and
Ma.Dm according to Parfitt et al. [16]) in the cross sections,
11 mm distal of femoral head in the subtrochanteric region
(Fig. 2). We measured at first the B.Dm of the cross
sections in a ventro-dorsal direction (in the middle of
section) and in a second step on the same line the Ma.Dm.
This provides the possibility to avoid many instrumental
and operator-dependent errors and it is easy to perform. The
B.Dm/Ma.Dm ratio helps us to compare the changes in the
cortex of subtrochanteric region of rat femur between all
groups.
Serum analysis
Blood samples (about 5 ml) were collected from the
decapitated animals, allowed to clot, and centrifuged at
3,000×g for 10 min. Serum was removed and stored at
−20°C until the electrochemiluminescence immunoassay
(ECLIA, Roche diagnostics, Mannheim, Germany) was
performed. For an anabolic marker, the level of osteocalcin
was analyzed by quantitative determination of the normal
minimally inhibitory dose of osteocalcin in the serum. For a
marker of bone resorption, the concentration of the ß-
crosslaps was quantitatively determined by analyzing the
degradation products of typ e - Ic o l l a g e ni nt h es e r u m
(ECLIA, Roche diagnostics, Mannheim, Germany).
Evaluation and statistics
The results of the right–left comparison were statistically
analyzed in an unconnected pair test (Prism TM, Graph
Pad, San Diego, CA, USA). The proportional difference
between the strengths of the right and left femurs was
determined in each rat, and the average value was
calculated. The average value of the proportional differ-
ences of the maximum load, failure load, yield load, and the
stiffness (elasticity) are signs of the reproducibility and the
quality of our new breaking test. In the comparative
bioassay, 11 rats per group were evaluated and compared.
Differences between the treatment groups were assessed
using one-way ANOVA tests (Statistica).
Results
Comparison of biomechanical parameters of right and left
femurs in the new breaking test
In the right–left comparison, the mean difference between
the trochanteric loads of the right and left femurs was 9.8%
Fig. 2 A radiograph of femoral cross section, 11 mm distal from
femoral head, to measure bone diameter (B.Dm = ab) and marrow
diameter (Ma.Dm = cd). The dorso-ventral line (ab) cuts the
horizontal medio-lateral line in the middle of marrow (the histo-
morphometry software finds this point) and builds a vertical angle
(90°). We used the dorso-lateral line for measuring of B.Dm and Ma.
Dm because we could observe on this axis the minimal anatomical
norm-variations in subtrochanteric region of rat femur. This region is
reliable and easy to evaluate
254 Osteoporos Int (2010) 21:251–261for the maximum load (Fmax), 11.5% for the failure load
(fL), 21.4% for the elasticity (stiffness), and 9.3% for the
yield load.
A graphical comparison of the strength of each femur in
individual rats showed great similarity. The scatter plots
from the results of the right–left comparison are presented
in Fig. 3.
Fracture classification
In 26 (86.7%) instances of the breaking test (evaluation
test, n=30), we observed reverse trochanteric fractures of
the femurs (type A3 according to AO-classification). A
comparison of all of these fractures revealed great
similarity not only in the localization but also in the form
of the fractures (Fig. 4a–b).
We also observed this fracture type in our compar-
ative bioassay of OVX rats (n=44). In the comparative
bioassay (sham, C, E, PTH), we observed in four cases a
tilt of the femoral head during the breaking test due to an
inaccurate breaking curve. These cases were not taken
into consideration. We presented here data only in
femurs (88.6%) with trochanteric fractures (39 from 44
fractures).
Breaking strength after administration of estradiol
or parathyroid hormone
Biomechanical changes in the left femurs were examined
after administration of estradiol and parathyroid hormone.
The biomechanical parameters Fmax and stiffness were
significantly higher in the PTH group (Fmax=225.3 N,
stiffness=314.9 N/mm) as compared to the C (Fmax=
166 N, stiffness=235.6 N/mm), E (Fmax=182.9 N, stiff-
ness=237.2 N/mm), and sham (Fmax=192.10 N, stiffness=
267.0 N/mm) groups. In the E group, the mean values of
the biomechanical parameters were higher than those of the
C group, but these differences were not significant. The
mean value of the yield load was in the PTH group higher
as compared to the E and C and sham group, but these
changes were statistically not significant (Table 1).
Histomorphometric changes in the proximal femur
after administration of estradiol and parathyroid hormone
The results of the histomorphometric analysis and micro-
architectural parameters are summarized in Table 1.
The results of Tb.Ar, N.Nd/mm
2, and Tb.Wi were
significantly higher in the PTH group (Tb.Ar=75.65%, N.
Fig. 3 Scatter plots from right–
left comparison of rat femurs in
the new breaking test. The mean
difference between the trochan-
teric loads of both femurs 9.8%
for the maximum load (Fmax),
11.5% for the failure load (fL),
21.4% for the stiffness (elastici-
ty), and 9.3% for the yield load
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2=41.32, Tb.Wi=9.80 µm) in comparison to the C
group (Tb.Ar=57.18%, N.Nd/mm
2=34.35, Tb.Wi=
7.62 µm). We found a significantly higher value for the
PTH compared to E groups concerning the Tb.Ar. Although
the mean values of Tb.Ar, N.Nd/mm
2, and Tb.Wi were
higher in the E-treated rats (Tb.Ar=61.04%, N.Nd/mm
2=
40.66, Tb.Wi=7.53) than in the C, these differences were
statistically not significant. The Tb.Wi in the PTH rats was
significantly higher compared to the sham animals (Tb.Wi=
8.5 µm; Fig. 5).
The mean of B.Dm/Ma.Dm ratio was in the PTH group
(1.938) significantly higher than C group (1.716). The
reason for this was mainly due to greater Ma.Dm in the C
animals. The E (1.749) and sham (1.740) rats showed a
higher B.Dm/Ma.Dm ratio than C but the results were not
statistically significant (Table 1).
Serum analysis
Serum osteocalcin levels differed between the groups (p<
0.05). The highest level of osteocalcin was observed in the
PTH-treated group (45.46 ng/ml), followed by the osteo-
porotic C group (17.78 ng/ml). In E-treated rats (5.35 ng/
ml), osteocalcin levels were lower than PTH. The concen-
tration of the ß-crosslaps in E- (46.86 ng/ml) and PTH-
treated (45.66 ng/ml) animals were slightly, but not
significantly, enhanced compared to the C group
(33.83 ng/ml; Table 1). The sham animals showed the
lowest level of ß-crosslaps (4.04 ng/ml) and osteocalcin
(2 ng/ml).
Fig. 4 Radiographs of proximal rat femur after breaking test. We
observed in 86.6% of cases (in right–left comparison) a reverse
trochanteric fracture (type A3 according to AO classification; a
anterior–posterior view, b lateral view)
Table 1 The results from comparative bioassay: body weight, biomechanical test, histomorphometry, and serum analysis
Sham OVX Estradiol benzoate Parathyroid hormone
Mean STD Mean STD Mean STD Mean STD
Body weight (g) 275.6
a 14.31 342.2 19.91 280.3
a 12.05 324.9
b,c 19.38
Serum analysis
Osteocalcin (ng/ml) 2
a 2.0 17.78 5.64 5.347
a 1.79 45.46
a,b,c 5.22
Crosslaps (ng/ml) 4.04
a 0.25 33.83 8.37 46.86 34.25 45.66
b 19.56
Biomechanical test
Maximum load (N) 192.1
a 20.49 166.03 38.36 182.92
b 13.83 225.25
a,b,c 46.55
Yield load (N) 120.2 16.48 111.57 31.33 113.14 10.04 132.00 18.69
Stiffness (N/mm) 267.0
a 26.10 235.56 40.82 237.15
b 45.40 314.87
a,b,c 72.05
Histomorphometry
N.Nd/mm
2 48.54
a 5.439 34.35 6.97 40.66
b 6.24 41.32
a 4.36
Tb.Ar (%) 77.25
a 10.73 57.18 13.62 61.04
b 8.27 75.65
ac 9.02
Tb.Wi (mcm) 8.5
a 1.38 7.62 0.95 7.53
b 1.25 9.80
abc 1.27
B.Dm (mcm) 3,154 135.9 3,137 280.6 3,140 161.1 3,151 124.1
Ma.Dm (mcm) 1,814 67.78 1,838 221.4 1,792 123.4 1,615
a,b,c 132.5
B.Dm/Ma.Dm 1.740 0.063 1.716 0.08 1.749 0.069 1.938
a,b,c 0.069
Tb.Ar ratio of trabecular area, N.Nd/mm
2 connectivity, Tb.Wi trabecular thickness, B.Dm bone diameter, Ma.Dm marrow diameter
aSham/E/PTH vs. OVX (p<0.05)
bE/PTH vs. sham (p<0.05)
cPTH vs. E (p<0.05)
256 Osteoporos Int (2010) 21:251–261Results of intravital fluorochrome labeling of cortical bone
of proximal rat femur
Using the digital imaging system, it was possible to
outline the regions labeled by the fluorescent agents.
Because of low color intensity of xylenol orange bands
(XO) and its overlabeling by CG, we measured the
different mineralization times mainly marked by the red
(AK), light green (CG and Xo), and yellow (TC) labels
(Table 2). The PTH group demonstrated the highest
bone remodeling and restoration activities on both
periosteal (34.6 mcm) and especially endosteal
(47 mcm and significantly higher than other groups)
surfaces. In contrast, in the E-treated animals, only a
minimal enhancement of bone remodeling of the
periosteal (5.2 mcm) and endosteal (6.9 mcm) side
was observed. In the C group, the periosteal remodeling
(21.8 mcm) seems to be less dramatic than in the PTH
group but the differences were statistically not signifi-
cant (Fig. 6). In the C rats, we did not observe any
endosteal appositions. The sham animals showed signifi-
cantly lower appositions in the periosteal (13.3 mcm) and
endosteal (14.7 mcm) side of the cortex in comparison to
the PTH group.
Discussion
Trochanteric fracture in the novel breaking test
The trochanteric fracture of the human femur is one of
the most frequent fracture types of osteoporotic skele-
ton. The trochanteric region of the rat femur shows
great similarity with the trochanteric area of the human
femur. Because there are many similarities between
human and rat bone at the cellular and tissue levels
(trabecular bone, endocortical envelope), the use of the
rat proximal femur is as good as any other routinely
used non-human skeletal site for assessing bone mor-
phometric changes [17]. The proximal (medial) part of the
femoral neck in rats and other large animals seems to not
be covered by periosteal tissue. This is an important factor
to consider, especially when anabolic agents are tested
with pronounced periosteal stimulation [18]. In contrast,
the trochanteric region contains a cortical surface covered
by a sufficient periosteum. Furthermore, the trochanteric
region has a high content of trabecular net.
The clear advantage of using the proximal femur is the
opportunity it provides to measure both cortical and
trabecular bone histomorphometric parameters as well as
mechanical properties of the bone within the same skeletal
area [19]. Biomechanical tests of this part of skeleton in
osteoporosis studies seem to be valuable and reliable.
The most conventional methods for evaluating rat hip
failure force are based on the axial compression
approach [14]. However, as most osteoporotic hip frac-
tures result from lateral falls, it seems logical and
necessary to establish mechanical testing methods closer
to clinical conditions.
In our study, the reproducibility of the biomechanical
test of the rat femurs was determined by comparing the
data from the right and left femurs of the non-OVX
rats. Our new breaking test yielded no significant
systematic differences concerning the mechanical char-
acteristics of the right and left femurs. Side comparative
studies in human and animals show intraindividual
variations of the same dimension that are found in our
right–left comparison. In humans, we know there are
differences (up to 15%) in size and strength of the right
and left lower extremity (anklebone) or upper extremity
(right- or left-handed person) [15]. The analysis of the
fracture type producing in our breaking test showed in
the right–left-comparison test in 86.6% and in the
biocomparative assay in 88.6% of the animals a
reversed trochanteric fracture of femur (type A3 accord-
ing to the AO classification). These results demonstrate
the high reproducibility of our new mechanical testing
method.
Fig. 5 Microradiographs of the proximal femur of rat show the high
content of both cortical and trabecular surfaces (after breaking test). a
The control group (C) with a low trabecular density. b The rat femur
after treatment with estradiol, c the sham group, and d after
substitution with PTH (high trabecular content and thick cortical shell)
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and parathyroid hormone
The antiosteoporotic effect of estrogen in OVX rats has
been shown in many recent studies [15, 20, 21]. This effect
has been confirmed not only by biomechanical tests but
also in histomorphometric analyses of different skeletal
sites, including the proximal tibia and lumbar vertebra.
It is known that hormone replacement therapy with
estrogen produces the best therapeutic effects in osteopo-
rosis that arises as a consequence of estrogen deficiency,
such as post-menopausal or ovariectomized conditions. The
antiosteoporotic effect of estrogen substitution is mainly
seen after an early substitution of this hormone.
While in the present study the mean values were clearly
higher in the E group in comparison to C rats, there were no
significant differences in the biomechanical tests between
the E and C groups. The possible reasons for this may be the
small number of animals, the short treatment period, and the
late therapy beginning with E (significant bone loss has
already occurred 8 weeks after OVX before E substitution).
The analysis of the results from the breaking tests
showed significant differences between PTH-treated vs.
sham and E-treated rats concerning stiffness and Fmax. The
known latency of E treatment in contrast to the pronounced
early anabolic effects of PTH on trabecular bone density
seems, in addition to the significantly higher endosteal bone
remodeling, to be the main reasons for the higher femoral
strength in the PTH group in comparison to both the E-
treated and the sham animals.
Histomorphometric changes after administration
of estrogen and parathyroid hormone
After estrogen treatment, we did not observed any
significant increases of the Tb.Ar, N.Nd/mm
2 of proximal
Table 2 The results from intravital fluorochrome labeling
Sham OVX Estradiol benzoate Parathyroid hormone
Mean STD Mean STD Mean STD Mean STD
Periosteal apposition
Absolute apposition band width (mcm)
Calcein green (days 0–18) 3.6
a 1.4 9.4 4.4 1.5
a,b 0.7 11.6
b,c 8.7
Alizarin red (days 18–24) 5.2 1.3 6.4 3.7 2.3
a,b 1.4 10.4
b,c 7.9
Tetracycline (days 24–35) 4.5 2.0 6.0 3.2 1.4
a,b 0.8 12.6
b,c 8.9
Sum 13.3
a 21.8 5.2
a,b 34.6
b,c
Absolute apposition band width per day (mcm)
Calcein green 0.2
a 0.1 0.5 0.2 0.08
a,b 0.04 0.6
b,c 0.5
Alizarin red 0.9 0.2 1.1 0.6 0.4
a,b 0.2 1.7
b,c 1.3
Tetracycline 0.4 0.2 0.5 0.3 0.1
a,b 0.07 1.1
b,c 0.8
Sum 1.5
a 2.1 0.6
a,b 3.4
b,c
Endosteal apposition
Absolute apposition band width (mcm)
Calcein green (days 0–18) 2.0
a 1.4 No significant appositions 2.3
a 1.2 17.8
a,b,c 3.5
Alizarin red (days 18–24) 2.7
a 2.3 3.2
a 1.7 14.0
a,b,c 3.5
Tetracycline (days 24–35) 0 0 1.4
a 0.7 15.6
a,b,c 4.6
Sum 4.7
a 6.9
a 47
a,b,c
Absolute apposition band width per day (mcm)
Calcein green 0.1
a 0.1 No significant appositions 0.1
a 0.06 1.0
a,b,c 0.2
Alizarin red 0.5
a 0.4 0.5
a 0.3 2.3
a,b,c 0.6
Tetracycline 0 0 0.1
a 0.06 1.4
a,b,c 0.4
Sum 0.6
a 0.7
a 4.7
a,b,c
The widths of apposition bands, calcein green, alizarin red, and tetracycline in cortical surface in subtrochanteric cross sections of rat femurs
(11 mm distal from femoral head) were measured by fluorescence microscopy (×400)
aSham/E/PTH vs. OVX (p<0.05)
bE/PTH vs. sham (p<0.05)
cPTH vs. E (p<0.05)
258 Osteoporos Int (2010) 21:251–261femur. In contrast, the PTH treatment induced a significant
increase of trabecular bone area and connectivity compared
to the C group. Although the B.Dm did not show any
significant changes between the groups, the results of the
B.Dm/Ma.Dm ratio demonstrated a significantly better
outcome in the PTH animals. As there were not any
significant changes concerning B.Dm, measured in the
subtrochanteric region of all femurs, the better B.Dm/Ma.
Dm ratios in the PTH rats seemed to be mainly caused by
an increase in endosteal bone formation of cortex. This
causes significantly lesser Ma.Dm in the PTH animals.
The cortical changes that are normally difficult to evaluate
could be reliably shown with the B.Dm/Ma.Dm ratio.
These results, in addition to the results of fluorescence
microscopy, provide useful information about intensity
and localization (endosteal and/or periosteal) of bone
remodeling (apposition) and drug influences within the
cortical area. The increased bone formation rate was
observed under PTH treatment both at the periosteal and
endosteal side by fluorescent-microscopic analysis of the
cross sections from the proximal femur. The endosteum
here seems to be one of the targets of PTH with an
accelerate bone formation and a pronounced filling in of
intracortical cavities [8, 22].
The significantly higher serum level of osteocalcin in the
PTH group confirms the strong anabolic effect of this
antiosteoporotic agent.
Although the estrogen is known to increase bone
m a s sa n ds t r e n g t hb yas u p p r e s s i o no fb o n er e s o r p t i o n ,
in our study, the biomechanical and histomorphometric
results of E were not significantly better than C group.
We have to point out here that in our study design,
8 weeks after OVX, a significant trabecular bone loss
has already occurred. The E substitution presented in
our study was not able to suppress the ß-crosslap level
in serum. In our opinion, the large standard deviation
concerning ß-crosslap level in the E rats makes an
adequate interpretation of these results difficult. How-
ever, the possible reasons for the weak antiosteoporotic
effect of E in our work may be the dose, length, and
especially the late beginning of E therapy. It is also
important to mention that the intensity of antiosteoporotic
effect of E and PTH seems, like that of many other
antiresorptive and anabolic drugs, can vary (stronger or
weaker) on different skeletal sites (vertebral body, tibia,…)
or in different species (rat, human, etc.).
According to our data, the higher endosteal bone
formation and the improvement of trabecular morphometry
Fig. 6 Transversal sections from the proximal femur (all sections
11 mm distal from femoral head, subtrochanteric region) of OVX rats
treated with PTH and E for 5 weeks and sham group. The sections
were studied by fluorescence microscopy. In the sham group, only a
minimal periosteal and endosteal bone formation could be observed.
In the OVX group, there was no endosteal but a clear periosteal
activity. The E-treated animals showed very weak periosteal and
endosteal appositions. In contrast, PTH seems to induce both
endosteal and periosteal bone formation. Please note the changes
between the groups concerning bone geometry and the width of bone
marrow (Ma.Dm) in the upper pictures
Osteoporos Int (2010) 21:251–261 259seem to be responsible for the better biomechanical results
in the PTH-treated rats in comparison to E and sham
group.
Our results provide a structural basis for the recent
demonstrations that PTH treatment seems to reduce the
incidence of osteoporosis-related fractures [23, 24], though
further experiments are needed to determine whether PTH
is also able to prevent trochanteric fractures. It is important
to mention here that all of these effects and differences
depend not only on the dose but also on the length of
treatment with E or PTH. It is thus necessary to conduct
dose- and time-related investigations in a second line of
inquiry.
In conclusion, we have introduced and validated a novel
method to produce trochanteric fracture for assessing the
strength of the trochanteric region of the rat femur. Our
findings indicate that PTH treatment increases bone
formation mainly on the endosteal and minimally periosteal
side of cortical area of the proximal femur in OVX rat and
also improves the trabecular micro-architecture. Our results
show that the trochanteric region of the rat femur (next to
the other skeletal sites) must also be mentioned as a further
skeletal location for studies of the antiosteoporotic effects
of drugs, as it contains both trabecular and cortical bone
with an intact periosteal shell.
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